Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?

Cancer chemotherapy and pharmacology - 1 Oct 2014

Chiu Chao-Hua, Chou Teh-Ying, Chiang Chi-Lu, Tsai Chun-Ming

Abstract excerpt

There is no argument over using epidermal growth factor receptor (EGFR) mutation status to guide the frontline treatment for advanced lung adenocarcinoma (LADC); however, the role of the testing in lung squamous cell carcinoma (LSQC) remains controversial. Currently, the guidelines/consensus statements regarding EGFR mutation testing in LSQC are not consistent among different oncology societies. American Society...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Consensus

Share to Drug Screening Assays, Antitumor

Share to ErbB Receptors

Share to Practice Guidelines as Topic

Share to Predictive Value of Tests

Source

Identifiers

PMID: 25053390
DOI: 10.1007/s00280-014-2536-3

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?PMID 25053390Read ↗

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer.Semantic proximity Read ↗

Detection and monitoring of driver mutations by next-generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR-tyrosine kinase inhibitors.Semantic proximity Read ↗

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Semantic proximity Read ↗

Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.Semantic proximity Read ↗

Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.Semantic proximity Read ↗

EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?Semantic proximity Read ↗

[Detection and Analysis of EGFR and KRAS Mutations in the Patients with Lung Squamous Cell Carcinomas].Semantic proximity Read ↗

Epidermal growth factor receptor mutations in lung adenocarcinoma.Semantic proximity Read ↗

The clinical value of genetic testing in lung squamous cell carcinoma: A retrospective studySemantic proximity Read ↗

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.Semantic proximity Read ↗

Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.